Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Novartis Ag (NVSEF) over the last 9 years, with Q4 2025 value amounting to $1.0 billion.

  • Novartis Ag's Accumulated Expenses rose 1598.22% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year increase of 1598.22%. This contributed to the annual value of $1.0 billion for FY2025, which is 1598.22% up from last year.
  • As of Q4 2025, Novartis Ag's Accumulated Expenses stood at $1.0 billion, which was up 1598.22% from $901.0 million recorded in Q4 2024.
  • Novartis Ag's Accumulated Expenses' 5-year high stood at $1.1 billion during Q4 2021, with a 5-year trough of $901.0 million in Q4 2024.
  • Over the past 5 years, Novartis Ag's median Accumulated Expenses value was $1.0 billion (recorded in 2025), while the average stood at $1.0 billion.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 1218.32% in 2024, then surged by 1598.22% in 2025.
  • Over the past 5 years, Novartis Ag's Accumulated Expenses (Quarter) stood at $1.1 billion in 2021, then fell by 2.75% to $1.1 billion in 2022, then fell by 3.12% to $1.0 billion in 2023, then decreased by 12.18% to $901.0 million in 2024, then rose by 15.98% to $1.0 billion in 2025.
  • Its Accumulated Expenses stands at $1.0 billion for Q4 2025, versus $901.0 million for Q4 2024 and $1.0 billion for Q4 2023.